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Abstract
Background: Chile has broad variations in weather, economics and population from the far desert
north (Region 1) to the cold, icy south (Region 12). A home-based self-collected vaginal sampling
was nested in the 2003 Chilean population-based health survey in order to explore the possibility
of a type-specific geographical variation for human papillomavirus
Methods: The population was a national probability sample of people 17 years of age and over.
Consenting women provided self-collected cervicovaginal swabs in universal collection media
(UCM). DNA was extracted and typed to 37 HPV genotypes using PGMY consensus PCR and line
blot assay. Weighted prevalence rates and adjusted OR were calculated.
Results:  Of the 1,883 women participating in the health survey, 1,219 (64.7%) provided a
cervicovaginal sample and in 1,110 (56.2% of participants and 66.5% of those eligible) the samples
were adequate for analysis. Refusal rate was 16.9%. HPV prevalence was 29.2% (15.1% high-risk
HPV and 14.1% low-risk HPV). Predominant high-risk types were HPV 16, 52, 51, 56 and 58.
Predominant low-risk HPVs were HPV 84, CP6108, 62, 53 and 61. High-risk and low-risk HPV rates
were inversely correlated between the regions. High-risk HPV prevalence was highest among the
youngest women, whereas low-risk HPV increased slightly with age.
Conclusion: Self-obtained vaginal sampling is adequate for monitoring HPV in the community, for
identifying high-risk areas, and for surveying the long term impact of interventions.
Background
The availability of highly effective human papillomavirus
(HPV) vaccines has led to a discussion about their incor-
poration in public health vaccine programs [1,2]. A base-
line characterization of HPV types in cervical cancers and
also in the general population is required before deciding
whether to introduce the vaccine. With this information
on the population genotype prevalence, together with
regional specific genotype distribution in cervical lesions
and cervical cancer, the potential impact of the vaccine
can be estimated. In a previous study of HPV prevalence
in cervical specimens of a population-based sample of
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women, we explored the individual risk factors for low-
risk and high-risk HPV infections, confirming that in
Chile the main risk factor was the number of sexual part-
ners for both high and low risk HPV [3]. This study aims
to describe the geographical distribution of the HPV types
in the national community. Epidemiologic studies of the
prevalence of HPV in the community have typically used
cervical samples obtained by a gynaecological examina-
tion [4]. Most women find this exam to be uncomfortable
[5]. Additionally, in countries where Papanicolaou (PAP)
screening is not widely accepted, studies based on gynae-
cological sampling may not represent the general popula-
tion. For community surveillance, public health officers
will need non-invasive methods that are acceptable to a
representative sample of women. One option is the self-
obtained vaginal sample. Various well-designed trials
have demonstrated that HPV detection using self-
obtained vaginal sample is a reasonable surrogate for the
identification of HPV types that are infecting the cervix,
with moderate to excellent agreement with the detection
of HPV from cervical samples obtained by clinicians [6-
10]. Agreement was better for the high-risk HPVs
[6,8,11,12]. Studies comparing acceptability of methods
demonstrated that most women preferred self-vaginal
sampling [5,8,13-19]. We assessed the prevalence and dis-
tribution of HPV types throughout Chile using self-
obtained vaginal sampling in the community. The
National Health Survey, ENS 2003, the first prevalence
study of chronic diseases, provided a population-based
national sample of non-institutionalized people aged 18
and above [20]. This is one of the first studies with self-
obtained vaginal sampling in a health survey for chronic
conditions in the adult population. The aims were to
assess the magnitude of the problem and to explore the
association of HPV prevalence with some regional charac-
teristics.
Chile is a long (6,435 km length) and narrow (200 km
wide) country (Figure 1) with a climate that goes from the
driest desert in the world, with a mean temperature of
18.1°C and 0 mm of rain/year in the extreme north
(Region 1) to a cold, windy and rainy (3,500 mm yearly)
climate in the far south (Region 12). The population in
the northern regions resides mostly in urban areas, with a
racial admixture of Hispanic and Andean Indians. Its
main economic activity is copper mining. Most of the
Chilean population lives in the central regions. The met-
ropolitan area (Region 13) is located between Regions 5
and 6; the climate is temperate with an average of 15°C
and an average annual rainfall of 150–200 mm. Its main
economic activity is industry and wine production. The
population is an admixture of Spanish with native
Mapuche Indians. The southern regions are mountainous,
with many lakes and rivers, and large rural population.
Average rainfall is 1,500–2,000 mm/year, with a tempera-
ture range of 2°C-23°C. This area hosts the largest ethnic
Mapuche population and is the poorest in the country. Its
main economic activity is agriculture and livestock pro-
duction. The far southern regions have a cold climate and
their principal activity is fisheries; its native population is
the lowest in the country.
Methods
Population and sample
The study population included all women participating in
the ENS 2003. The sample for the ENS 2003 was a
national stratified multistage probability sample of non-
institutionalized people aged 18 years and above, repre-
senting the Chilean population and comparing regions,
rural and urban, four age groups, and three socio-eco-
nomic strata. The sampling error was set at less than 2%.
The ENS 2003 is the first household based health survey
with biological sampling (blood, urine) body measure-
ments (height, weight, waist circumference), clinical
examinations (visual and auditive acuity, dental health)
and comprehensive health questionnaires administered
by a public health certified nurse and a trained inter-
viewer. Only one subject, selected by the Kish method,
participated per household [21]. The survey was con-
ducted from June to December 2003. The ethics commit-
tees of the Catholic University and the Ministry of Health
reviewed and approved the study. All women signed a
separate informed consent for the self-obtained vaginal
sample.
Self-obtained vaginal sampling
After receiving information about the exam and providing
written informed consent, eligible women who were not
menstruating, not pregnant, had not had sexual relations
the previous day, with no prior hysterectomy, and had ini-
tiated sexual activity were taught, using pictorial pam-
phlets, how to obtain a vaginal sample. The nurse
provided a Digene sachet containing a conical brush and
a tube with the transport media (Universal Collection
Media, UCM) [22]. Women were instructed to introduce
the brush deep into their vagina and turn it smoothly once
towards the left and then towards the right. They then
were instructed to place the brush in the tube, cover it with
a lid and give it to the nurse. Tubes were transported and
stored at 4°C until processing. Most samples were proc-
essed 35 days after the exam was taken, with a range of 10
days to four months, with no difference in positivity rate
with regard to the time elapsed before processing. A PAP
screening was recommended for women with an HPV
positive result.
Laboratory analysis
In the Catholic University Pathology Laboratory, DNA
from the self-obtained vaginal sample was extracted with
the DNeasy tissue kit (Qiagen, Valencia, CA USA) follow-BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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Relative Risk of cervical cancer mortality by county of residence Figure 1
Relative Risk of cervical cancer mortality by county of residence. Chile average 1985–2002(1) 1: Prepared by the authors based 
on Ministry of Health mortality and population data.BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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ing the manufacturer's instructions. All extracted DNA
samples were sent to Johns Hopkins University where
they were typed using PGMY consensus PCR and proto-
type line blot assay (Roche Molecular Systems) to identify
37 HPV genotypes [23-25]. DNA extraction, PCR set-up
and amplification/detection were conducted in separate
laboratories using dedicated instruments to minimize
contamination. Specimens were opened only after brief
centrifugation using clean Kim-wipe to avoid specimen-
to-specimen carryover. Each 96 well PCR plate included
eight DNA negative controls. HPV 16 and 18 positive plas-
mid controls in a background of 50 ng/ml human placen-
tal DNA at high (approx 5000 copies/PCR) and low
(approx 25 copies/PCR) concentration were also included
in each PCR assay. Two negative controls per detection
tray were included to ensure no spill over during hybridi-
zation.
Collection of secondary data from Chilean Regions
To explain the variation in the prevalence of HPV among
the 13 Chilean Regions, we collected available regional
population data for women's characteristics (fertility rate,
educational level, smoking rate), socio-demographic
characteristics (life expectancy, percent Amerindians, per-
cent single, poverty index, age distribution), access to
health care (Papanicolaou coverage), HIV prevalence rate
(indicator of sexually transmitted diseases) and cervical
cancer mortality. We obtained mortality data and health
information from the Ministry of Health and population
data from the National Institute of Statistics.
Statistical analysis
Prevalence rates were calculated using sampling weights
based on the two stage sampling design and adjusted for
post stratification population totals using the Chilean
2003 population statistics. Considering the complex sam-
ple design, the standard error and 95 percent confidence
intervals were calculated with the Taylor linear approxi-
mation method using SPSS version 14 [26]. Adjusted OR
for high-risk and low-risk infections were calculated from
a Multivariate Logistic Regression Model for Complex
Samples. Age adjusted high risk and low risk HPV preva-
lence, were calculated with a general additive model using
R software. For the exploratory regional-level analyses of
HPV and some regional characteristics partial correlations
were used adjusted by age and multivariate linear models
using SPSS 14.
Results
Survey response rates
A total of 1,883 women participated in the ENS2003; 12%
were not eligible – reasons for ineligibility included
women currently menstruating, having had sexual inter-
course less than 24 hours previously (9.1%), or prior hys-
terectomy (2.9%); 8.1% could not be included because
the interviewers did not have swabs when conducting the
survey; 16.9% refused to take the self-sample leaving a
total of 1,219 (64.7%) women who provided a self exam.
109 (8.9%) of the samples were insufficient for HPV anal-
ysis as indicated by the absence of the human beta-globin
control amplification (1.6%) or were untested because
the tube was broken or empty. Therefore, 1,110 women
(56.2% of the participants and 66.5% of the eligible
women) provided an analyzable vaginal sample. Women
refusing to collect the sample were similar to those who
accepted the exam with regard to region of residence and
urban-rural zone, but higher refusals were observed
among the younger (< 25 years old), the older (> 60 years
old), the lower educational group, the single, and the wid-
owed.
Population characteristics
The mean age of the survey participants was 41.9 years
(range 16–97) and the majority lived in urban areas
(88.1%) (Table 1). The mean number of years of educa-
tion was 9.4 (range 0–22); 26% had less than 4 years of
education. The majority of participants (62.5%) were
unemployed (i.e., not working or studying) and were
married or cohabiting (66%). The survey population was
reasonably well-screened, with 85% of women reported
having a previous Papanicolaou smear (62% in less than
3 years), and 2.6% reporting having had a previous abnor-
mal Papanicolaou smear. The regional distribution of par-
ticipants represents the baseline population.
Acceptability of self-sampling
Most women [89.6%, (95% CI 86.8–91.9)] reported no
discomfort with the self-administered swabs and the
majority [79.4% (95%CI 75.9–82.6)] indicated self sam-
pling caused less discomfort than the Papanicolaou smear
(manuscript in preparation).
HPV prevalence: Regional variation by risk group
Overall, we observed 29.2% point prevalence for any HPV
infection in a population-based survey of adult Chilean
women. Of the infected women, 146 (15.3%) had at least
one high risk HPV genotype detected and 83 (8.4%) had
exclusively high-risk HPV types. Only low-risk HPV types
were detected in the remaining infected women (162, or
13.9% of the survey population). A total of 488 infections
were identified (some women may be infected with more
than one HPV type); of those 202 (41.4%) were caused by
high-risk HPVs and 286 (58.6%) by low-risk HPVs. HPV
16 was the predominant type of high-risk HPV, followed
by HPV 52, 51, 56 and 58. Among the low-risk HPVs the
most frequently detected types were HPV 84, CP6108, 62,
53 and 61 (Table 2).
Total HPV infection (high-risk plus low-risk HPVs) varied
from 43.5% (95% IC, 23.5–65.9) in Region I (the north-BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
Page 5 of 12
(page number not for citation purposes)
ernmost region) to 25% (96% CI, 15.6–36.6) in Region V
(Figure 2). Prevalence of high-risk (either single or multi-
ple) and low-risk HPVs (single or multiple low-risk only)
rates were inversely correlated between the regions (Pear-
son correlation -0.62 p= 0.023). Although not statistically
significant the age distribution varied between the regions
with the lowest mean age in Region I and the highest in
Region XII (mean age in years 38.6 and 45.0, respec-
tively). When weighted and age-adjusted, this inverse
association between high and low-risk HPVs decreased
and lost its statistical significance (age adjusted partial
correlation -0.36 p = 0.25). Based on the relative contribu-
tion of a high-risk HPV to the total burden of HPV, four
distinct macroregions were identified: the North (adjacent
to Peru and Bolivia), Central, South, and Extreme South
(Patagonia). The OR of having high-risk HPVs was 2.8
(95% CI 1.4–5.7), 0.9 (95% CI 0.6–1.5), 0.6 (95% CI
0.3–0.98) and 1.09 (95% CI 0.4–3.0), for the North, Cen-
tral, South and Extreme South areas respectively. The
mean ages of the population were: 39.8, 42.7, 41.1 and
40.0 for North, Central, South and Extreme South regions,
respectively. Neither high-risk HPV nor low-risk HPV was
associated with cervical cancer mortality (Pearson correla-
tion 0.2 and 0.1 respectively; test for trend, p = 0.29 and
0.37, respectively). In 2004, according to the ministry of
health statistics, the Papanicolaou coverage for women
35–64 years old varied from 54.7% in the Metropolitan
South-eastern Health Service to 87.3% in the Metropoli-
tan Central Health Service. Nevertheless, Papanicolaou
coverage was not significantly associated with either high-
risk (Pearson correlation 0.15 p = 0.6) or low-risk HPV
(Pearson correlation -0.35 p = 0.23).
The prevalence of current smokers, birth-rate and male-
female ratio (number of men divided by number of
women in the baseline population) correlated signifi-
cantly with the prevalence of high-risk HPV (Pearson cor-
relation and p values 0.63, 0.01; 0.47, 0.05 and 0.47, 0.05,
respectively). Prevalence of current smokers, prevalence
rate of HIV and proportion of singles, were inversely cor-
related with low-risk HPV (Pearson correlation and p
value -0.45, 0.059; -0.50, 0.04, respectively and 0.43,
0.069).
Individual risk factors for HPV infection
High-risk HPV prevalence was highest in the younger age
group (under 25 years old) and declined significantly with
age (Figure 3). Low-risk HPV had a positive but not statis-
tically significant increase with age (Figure 4). Single
women had a higher prevalence of high-risk HPV infec-
tion (OR = 3.7 95% confidence interval (CI) 2.1–6.6)
while women who were older (OR = 0.29, 95% CI;
0.1–0.8) and living in a rural area (OR = 0.25 95% CI
0.1–0.7) were significantly less likely to have prevalent
high-risk HPV (Table 3). Ever having had a Papanicolaou
was unrelated with either high-risk or low-risk HPV. We
found no association between either high-risk or low-risk
HPV and years of education. After multivariate adjust-
ment, the only risk factors for low-risk HPV were being
separated (OR = 2.1 95% CI 1.2–3.7) and residing in the
southern regions (OR = 2.3 95% CI 1.4–3.7) (Table 3).
Discussion
Surveillance of adult health status and its risk factors has
become an essential tool for public health planning and
evaluation. To date this surveillance has focused on cardi-
ovascular diseases and its risk factors and, therefore, this is
one of the first surveys to incorporate HPV testing as one
of the priority problems for adult health surveillance. The
overall prevalence of any HPV was strikingly similar to a
recent US national survey using similar methods; however
we did note an interesting contrast between high-risk and
Table 1: Characteristics of the 1 110 women studied and 
weighted percents.
Characteristics (n) (n) weighted percent *
Age (years)
18–24 (102) 13.1
25–29 (73) 10.2
30–34 (104) 13.4
35–39 (90) 11.6
40–44 (114) 11.6
45–49 (129) 10.7
50–54 (109) 8.4
55–59 (94) 6.2
60–64 (83) 5.8
> = 65 (212) 9.0
Education
High (128) 16.6
Medium (556) 57.2
Low (426) 26.2
Marital status
Married/Cohabiting (674) 65.8
Widow (121) 5.3
Separated (85) 5.7
Single (228) 23.1
Smoker
No (735) 60.1
Yes (367) 39.9
Pap ever
Yes (939) 84.6
No (167) 15.4
Residence
Urban (947) 88.1
Rural (163) 11.9
Region
North 12.0% (10.5–13.7)
Central 54.0% (50.3–57.6)
South 32.9% (29.7–36.3)
Extreme South 1.1% (0.8–1.4)
*::using sampling weights and adjusted for post stratification 
population totals.BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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low-risk HPV prevalence and regional variability that was
not previously reported [27].
In the multivariate analysis, residing in the north of Chile
was a risk factor for high-risk HPV infection. The relative
contribution of high risk HPV to the total burden of HPV
infection was almost 3 times higher in the north than the
national average while in the south it was almost half the
national average [OR 2.8 (95% CI, 1.4–5.7) and 0.6 (95%
CI, 0.3–0.98), respectively]. The relative excess of high-
risk types in the north appears to be associated with a
younger age and with variations in factors associated with
sexual behaviour. While we could not explore sexual
behaviour directly, secondary data shows that northern
regions have higher rates of smoking, higher birth rates
and higher rates of HIV while they are less rural and have
Table 2: HPV infections by HPV types in vaginal samples of 1,110 women from the National Health Survey 2003.
HPV type Single Multiple Total (crude %) % adjusted* 95% CI adjusted
HPV - 802 (72.3) 70.8 (66.3–74.9)
HPV + 208 100 308 (27.7) 29.2 (25.1–33.7)
HR HPV+ 70 76 146 (13.2) 15.3 (11.9–19.3)
HR HPV only 70 13 83 (7.5) 8.4 (5.9–11.8)
LR HPV+ only 138 24 162 (14.6) 13.9 (11.2–17.2)
HR infections
16 19 10 29 (2.6) 3.2 (1.6–6.3)
18 1 5 6 (0.5) 0.3 (0.1–0.8)
31 5 7 12 (1.1) 1.2 (0.6–2.5)
33 1 5 6 (0.5) 0.4 (0.2–1.2)
35 4 6 10 (0.9) 1.1 (0.5–2.2)
39 4 7 11 (1.0) 1.3 (0.5–3.2)
45 5 7 12 (1.1) 0.9 (0.4–1.8)
51 6 11 17 (1.5) 2.1 (1.0–4.3)
52 5 19 24 (2.2) 2.6 (1.3–4.9)
56 4 11 15 (1.4) 2.0 (0.8–4.9)
58 2 17 19 (1.7) 1.7 (1.0–3.0)
59 7 4 11 (1.0) 1.6 (0.7–3.3)
66 3 9 12 (1.1) 1.6 (0.6–4.0)
68 3 5 8 (0.7) 0.5 (0.2–1.2)
73 1 9 10 (0.9) 1.0 (0.5–2.3)
Subtotal 70 132 202
LR infections
6 5 4 9 (0.8) 1.2 (0.5–2.6)
11 1 0 1 (0.1) 0.1 (0.0–1.0)
26 1 1 2 (0.2) 0.1 (0.0–0.4)
40 1 2 3 (0.3) 0.2 (0.0–0.8)
42 2 10 12 (1.1) 1.2 (0.6–2.4)
53 8 16 24 (2.2) 2.6 (1.2–5.6)
54 2 6 8 (0.7) 0.3 (0.1–0.7)
55 4 3 7 (0.6) 0.6 (0.2–1.7)
61 20 15 35 (3.2) 2.3 (1.4–3.8)
62 10 16 26 (2.3) 3.1 (1.8–5.3)
64 3 0 3 (0.3) 0.1 (0.0–0.3)
67 4 5 9 (0.8) 1.4 (0.5–4.0)
70 9 12 21 (1.9) 1.8 (1.1–3.1)
71 6 13 19 (1.7) 1.3 (0.7–2.7)
72 10 1 11 (1.0) 1.0 (0.4–2.2)
81 9 9 18 (1.6) 2.0 (1.0–4.0)
83 8 4 12 (1.1) 0.8 (0.3–1.7)
84 21 14 35 (3.2) 3.7 (2.3–6.1)
CP6108 12 14 26 (2.3) 3.2 (1.8–5.5)
IS39 2 3 5 (0.5) 0.8 (0.2–2.3)
Subtotal 138 148 286
Total 208 280 488
HR: high-risk, LR: low-risk; *::using sampling weights and adjusted for post stratification population totalsBMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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less poverty than the southern regions (data not pre-
sented). On the other hand, the excess of low- risk HPV in
the south appears to be associated with older age, poverty
and rurality. Other authors have also described a diverse
epidemiological profile for low and high risk HPVs [4,28].
To explain the differences in the relative distribution of
high and low risk HPV, some authors have suggested an
antagonism between high-risk and low-risk HPVs. In a
serologic case-control study, Luostarinen, et al. [29]
Age prevalence of low-risk HPV in vaginal samples from the  population Figure 4
Age prevalence of low-risk HPV in vaginal samples from the 
population. National Health Survey, Chile 2003.
Regional distribution high-risk and low-risk HPV in the population of Chile's 13 Regions Figure 2
Regional distribution high-risk and low-risk HPV in the population of Chile's 13 Regions.
Age prevalence of high-risk HPV in vaginal samples from the  population Figure 3
Age prevalence of high-risk HPV in vaginal samples from the 
population. National Health Survey, Chile 2003.BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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describe a statistically significant null association with cer-
vical cancer risk among women who are seropositive to
both HPV 6/11 (OR = 1.0) and HPV 16, relative to HPV 6/
11 alone (OR = 2.2) or HPV 16 alone (OR = 5.5). Simi-
larly, Wheeler, et al. [30] observed that women who had
no HPV had a five times higher probability of acquiring
HPV 16 in the following two years than women who car-
ried low-risk HPVs (authors' calculation from Table 2 of
Wheeler 2006). These reports, coupled with our ecologic
observational data of an inverse correlation between low
Table 3: Risk factors for HPV infection among the 1 110 women, National Health Survey, Chile 2003.
Characteristics (n) HR HPV Crude OR Adjusted OR LR HPV only Crude OR Adjusted OR
(95% IC) (95% IC) (95% IC) (95% IC) (95% IC) (IC 95%)
n = 146 n = 162
Age (years)
18–29 26.8 1.0 1.0 13.7 1.0 1.0
(18.5–37.1) (8.2–22.0)
30–49 13.9 0.5 0.7 13.0 1.3 0.8
(9.1–20.7) (0.3–0.9) (0.4–1.4) (9.2–18.1) (0.7–2.4) (0.3–2.0)
50–64 8.5 0.8 0.4 15.6 1.3 0.9
(5.7–12.5) (0.4–1.4) (0.2–0.99) (10.4–22.6) (0.7–2.6) (0.3–2.3)
> = 65 8.0 0.4 0.3 16.1 1.8 0.9
(4.6–13.5) (0.2–0.99) (0.1–0.8) (10.7–23.6) (0.8–3.8) (0.3–2.4)
Education
High 17.0 1.0 1.0 16.2 1.0 1.0
(9.2 – 29.3) (8.5–28.5)
Medium 16.7 0.8 1.2 12.6 0.7 0.7
(12.0 – 22.8) (0.4–1.3) (0.5–2.9) (9.5–16.6) (0.4–1.2) (0.3–1.6)
Low 11.0 0.9 1.4 15.4 0.6 0.8
(7.6 – 15.8) (0.5–1.7) (0.6–3.8) (11.0–21.2) (0.3–1.1) (0.4–2.0)
Marital st 10.0 1.0 1.0 12.9 1.0 1.0
Married/Cohabiting (6.7–14.7) (9.7–17.1)
Widow 12.9 2.0 2.3 21.4 1.8 1.9
(6.7–23.1) (1.02–3.9) (0.9–5.4) (13.5–32.2) (1.1–3.3) (0.9–3.7)
Separated 6.8 1.1 0.7 26.5 2.1 2.5
(3.0–14.4) (0.5–2.3) (0.2–2.0) (14.8–42.6) (1.2–3.7) (1.1–5.7)
Single 33.2 2.7 3.7 12.3 1.3 0.9
(24.8 – 42.8) (1.7–4.2) (2.1–6.6) (7.6–19.2) (0.83–2.2) (0.5–1.7)
Smoker
No 11.8 1.0 1.0 13.9 1.0 1.0
(8.3 – 16.6) (10.6–18.1)
Yes 20.6 1.3 1.46 14.1 1.18 1.1
(14.5 – 28.4) (0.9–1.9) (0.8–2.8) (10.0–19.6) (0.8–1.7) (0.6–1.9)
Pap ever
Yes 14.0 1.0 1 13.9 1.0 1.0
(10.4–18.6) (10.9–17.5)
No 21.9 0.99 0.8 14.0 1.13 0.9
(13.6–33.3) (0.6–1.7) (0.4–1.7) (8.4–22.4) (0.7–1.9) (0.4–1.9)
Residence
Urban 16.7 1 1.0 13.6 1.0 1.0
(12.9 – 21.2) (10.7–17.1)
Rural 5.0 0.4 0.2 16.8 1.3 1.08
(2.1 – 11.2) (0.2–0.8) (0.1–0.7) (10.2–26.5) (0.8–2.1) (0.6–2.1)
Region
North 22.7 1.0 1.0 8.5 1.0 1.0
(16.6–30.3) (4.5–15.6)
Central 13.9 0.5 0.6 12.8 1.7 1.5
(9.0–20.8) (0.3–0.9) (0.3–1.1) (8.9–18.1) (0.9–3.0) (0.7–3.5)
South 14.5 0.6 0.7 18.0 2.3 2.4
(9.9–20.6) (0.4–0.88) (0.4–1.3) (14.0–22.9) (1.4–3.7) (1.1–5.0)
Extreme South 24.7 0.83 1.5 15.9 1.9 1.9
(11.8–44.7) (0.4–1.8) (0.5–4.6) (6.9–32.4) (0.8–4.6) (0.6–5.9)BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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and high risk HPV infections, not entirely controlled by
age adjustment, point to possible immunological interac-
tions between the cervicovaginal HPV flora that require
further investigation.
The age-specific prevalence of HPV were the same in the
current survey and in our previous study, with high-risk
HPV prevalence peaking below 25 years old while low-
risk HPV increased slowly after age 50 [3]. The increase in
the prevalence of low-risk HPV in older ages has been
reported in some studies in Latin America and Spain [31-
33] and confirmed in a recent meta-analysis [34], whereas
others have found a flat age curve for low-risk HPV
[25,35,36]. Some authors have attributed the excess of
low-risk HPV in older women to the elimination of high-
risk HPV by the screening programs [35]. It is intriguing
that while low-risk HPV incidence at younger ages is half
as frequent and in some reports is undetectable twice as
fast as high-risk HPV [37-39], it increases in frequency at
older ages both in screened and unscreened women [40].
A recent study by Wheeler found the same 2 year clearance
rate for low-risk (36%), high-risk except 16 (41%) and
HPV 16 (34%) (calculated from Table 3 in Wheeler
2006). The possibility that low-risk HPV in adult popula-
tions results from frequent reactivation or re-infection
should be considered in view of these data.
When comparing the HPV types found in these vaginal
samples with the published data on HPV types isolated
from cervical samples in Chile's general population [3] we
found a remarkable coincidence in the distribution of
high-risk HPV types (Fig 5) in vaginal and cervical swab
samples. However, we found no similar correlation in the
most frequent low-risk types (Figure 6). HPV DNA posi-
tivity was assessed in the cervical sample using a general
primer-mediated GP5+/6+ polymerase chain reaction
(PCR) and an Enzyme Immune Assay (EIA), to detect 36
HPV types (Ferreccio 2004), while in the current study, as
already described, DNA was extracted and typed using
PGMY consensus PCR and line blot assay to 37 HPV gen-
otypes. However, these methods have been shown to have
similar test characteristics, with difference in the detection
of only 3 types: 35, 53 and 61 [41]. These results suggest
that while self-collected vaginal swabs may result in
higher low-risk HPV prevalence estimates compared to
cervical swab samples, the concordance for high-risk, clin-
ically relevant HPV is high [9,12,42].
Types of High-risk HPV isolated from cervical samples in 2000 in Santiago and from vaginal self-collected samples in 2003 all  Chile Figure 5
Types of High-risk HPV isolated from cervical samples in 2000 in Santiago and from vaginal self-collected samples in 2003 all 
Chile. Note: the asterisks denote a significant Chi square test with a p value <0.05 for the difference in the proportion 
between cervical and vaginal samples.BMC Public Health 2008, 8:78 http://www.biomedcentral.com/1471-2458/8/78
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Self-sampling was highly acceptable for Chilean women,
as has been repeatedly demonstrated in different cultural
settings in Canada [18], USA [16], Germany [13], Mexico
[5], Brazil [19], Africa [8] and China [43]. Collectively,
these data suggest that vaginal self-collected swabs could
be effectively used for primary cervical cancer screening
via HPV DNA testing. This application was particularly
useful for those women who had never been screened,
70% of whom agreed to self-sample in our survey.
There are several caveats in the interpretations and gener-
alizations based on this population-based survey of HPV
type-specific prevalence. The relatively low response rate
may bias the results. Nevertheless, since the non-partici-
pants are weighted, part of the bias may have been
removed. We estimated the bias by correcting the esti-
mates based on propensity scores, but the estimated prev-
alence changed minimally (Vives A. manuscript in
preparation), therefore we believe that these biases do not
significantly change our inferences.
The most important limitation in estimating the real HPV
burden is the fact that we are measuring HPV at a single
point in time, with no information about the historical
exposure of these women to HPV. Winer and colleagues
[44] estimated a cumulative HPV incidence of 32% after 2
years of follow-up among young college women. HPV
seroprevalence (cumulative lifetime exposure estimate)
have been generated from a population survey [45,46],
with an average 15% – 25% cumulative exposure to HPV
16 alone. Compared to the 3.2% HPV 16 DNA observed
in this population, clearly cervicovaginal HPV DNA point
prevalence is not a valid marker of ever having been
exposed to the virus.
Conclusion
Self-obtained vaginal sampling is an adequate method for
monitoring the burden of HPV in the community. Cou-
pling this sample collection with routine census proce-
dures allows high-risk areas to be identified in order to
prioritize interventions and to carry out routine surveil-
lance to assess the impact of the interventions (e.g., HPV
prophylactic vaccination) over time.
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